


Remarks

Claims 1-17, 19, 21-25 and 27-28 are pending in this application. Claims 18,20, 26 and 29 have been cancelled. Claims 1-17, 19, 21-25 and 27-28 have been amended. No new matter has been added.

By way of this preliminary amendment, claims 1-17, 19, 21-25 and 27-28 have been amended. These claim amendments are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments.

In view of the above amendments and arguments, this application is deemed to be in a form suitable for US prosecution.

Respectfully submitted,



Dr. Tilman Breitenstein
Limited Recognition Under 37 CFR § 11.9(b)
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175

Phone: (203) 812-2226

Date: March 10, 2025